Molecular mechanisms of acquired proteasome inhibitor resistance.
about
Panobinostat for the treatment of multiple myeloma: the evidence to dateCircumvention of Mcl-1-dependent drug resistance by simultaneous Chk1 and MEK1/2 inhibition in human multiple myeloma cellsAntileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsThe resistance mechanisms of proteasome inhibitor bortezomib.The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.Multicolor monitoring of the proteasome's catalytic signature.Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome.Expression of immunoproteasome genes is regulated by cell-intrinsic and -extrinsic factors in human cancersHigher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.Cx43 expressed on bone marrow stromal cells plays an essential role in multiple myeloma cell survival and drug resistanceSuppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers.Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.Modulators of HIF1α and NFkB in Cancer Treatment: Is it a Rational Approach for Controlling Malignant Progression?Proteasome inhibitors in acute leukemia.Peptide-based proteasome inhibitors in anticancer drug design.Carfilzomib in multiple myeloma.Proteasome inhibitors as experimental therapeutics of autoimmune diseases.A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cellsWhen Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response.Natural compounds for pediatric cancer treatment.Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.p62/SQSTM1 is involved in caspase-8 associated cell death induced by proteasome inhibitor MG132 in U87MG cells.Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.DNA damage-induced ubiquitylation of proteasome controls its proteolytic activity.PAX3-FOXO1 induces up-regulation of Noxa sensitizing alveolar rhabdomyosarcoma cells to apoptosis.Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma.Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis.Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.(Immuno)proteasomes as therapeutic target in acute leukemia.
P2860
Q26778674-40759DB7-BDDF-4C81-BA8F-04063E64A010Q28540339-1BE89816-914D-4364-9D8B-3C5C5BE84CFDQ33742779-8762DE20-4E22-4FE7-AF0A-6891B7C01E28Q34218976-02700F4C-F571-4D10-B66A-54B02CB83AC2Q34256126-CB0F5E80-4622-4590-9B98-65ECA160C1CFQ34602263-7B0332CC-EF1B-4C33-BB75-265F21776A6FQ35005087-5BE01154-1D1F-43BA-B0D5-681EA66E8C21Q35121111-84ECD23C-B494-49D1-B5D0-84966EFE3873Q36002378-F8592CA8-B17F-4874-AAB3-E36BD8DB809CQ37278032-8FC86B37-7875-4933-A33D-3AFFCAF0A151Q37377911-009C0668-292B-4E3E-8E2C-E05D8FA89C01Q37549419-7F7E7B8E-42F4-47CF-B910-68B1E581A3A6Q37590014-6640A17F-9CE0-4A98-9235-A4D191F04FD6Q37688848-18EF1FEE-4E80-4021-95E0-27A993A0CAEBQ38081415-898FD987-BB4A-44A5-A286-0919973733A6Q38088003-7A065D80-B945-42E8-994E-C2087495685FQ38192572-2F78A6EC-48A6-4EDA-8E8E-96CC6E11EFABQ38244558-B6EBD952-92F5-4A63-B86F-3F66889CE1CCQ38427697-2A3BFD32-7A2A-43BA-9C53-B539AB7FD9B7Q38444221-3EC37FE2-E4DD-4E12-9BA4-EA5979B38A1DQ38503345-8FD54477-EB98-4FDE-82BB-4DA2324ADEB6Q38663897-A7C103DF-79A3-461A-97E7-3A77BFCA6368Q38986185-38C60049-6FA4-48D4-A2D1-C1A78D006E71Q38997499-5CB30DD6-C959-4A61-9256-12BB337662FDQ39034873-2E99F82E-FE5A-4EA9-B6CF-DB60F7A1DB0AQ39116807-A813E429-2A77-4E62-B43B-80D92ADE9FB1Q39132575-291F79E8-724F-431B-AB46-627C559B54A7Q40701267-3FAFD839-F69F-4F9C-8D8E-E1ED0C3B8AE0Q41583227-39BB0F76-B9D0-4B3D-9DDD-963F0DBCF7AEQ41607725-93E80EB1-9664-418C-88E1-F7F88D5126A7Q47131929-571FF92D-17F2-47B8-A185-769A3F40D8DD
P2860
Molecular mechanisms of acquired proteasome inhibitor resistance.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Molecular mechanisms of acquired proteasome inhibitor resistance.
@en
Molecular mechanisms of acquired proteasome inhibitor resistance.
@nl
type
label
Molecular mechanisms of acquired proteasome inhibitor resistance.
@en
Molecular mechanisms of acquired proteasome inhibitor resistance.
@nl
prefLabel
Molecular mechanisms of acquired proteasome inhibitor resistance.
@en
Molecular mechanisms of acquired proteasome inhibitor resistance.
@nl
P2860
P356
P1476
Molecular mechanisms of acquired proteasome inhibitor resistance.
@en
P2093
Andrew J Kale
P2860
P304
10317-10327
P356
10.1021/JM300434Z
P407
P577
2012-10-03T00:00:00Z